Corpus overview


Overview

MeSH Disease

Transmission

Seroprevalence
    displaying 1 - 10 records in total 18
    records per page




    On Cancer, COVID-19 MESHD and CT Scan: A Monocentric Retrospective Study

    Authors: Francesca Martini; Andrea D'Alessio; Federico Bracchi; Daniela Di Mauro; Anna Fargnoli; Marco Motta; Cristina Giussani; Marco Meazza Prina; Giovanni Gobbin; Monica Taverna

    id:10.20944/preprints202009.0075.v1 Date: 2020-09-04 Source: Preprints.org

    Background The acknowledgment of computed tomography (CT) defined diagnosis in high prevalence SERO northern Italy may identify more patients with Coronavirus Disease MESHD-2019 (COVID 19) infection, than RT-PCR alone. Methods We retrospectively reviewed 148 chest CT scans of oncological patients who were referred to the Radiological Unit of Policlinico S. Marco from 1st of February 2020 to 30th of April 2020, during the Covid-19 MESHD outbreak in Bergamo area. Therefore, we analyzed RT-PCR tests of these 148 patients. Results Among 32 patients with diagnosis of COVID-19 MESHD infection: 17 patients were asymptomatic TRANS or had mild symptoms (53.1%), while 15 developed severe disease (46.8%). The incidence of COVID-19 MESHD infection is 22.9%, the mortality rate is 18.8%. Severe COVID-19 MESHD disease is associated with higher median age TRANS. We did not find any correlation between disease severity and sex, smoke or cardiovascular comorbidities. Remarkably, patients who were on treatment developed milder disease MESHD than cancer MESHD patients who were not on treatment. Conclusions The acceptance of CT-defined diagnosis in high prevalence SERO area like Bergamo highlighted a larger number of COVID-19 MESHD oncological population than RT-PCR alone, in particular asymptomatic TRANS and mild symptomatic patients. We observed that actively treated patients had milder disease, according to previous studies that suggested a protective role of immunosuppression.

    Markers of NETosis and DAMPs are altered in critically ill COVID-19 MESHD patients

    Authors: Joram Huckriede; Sara Bülow Anderberg; Albert Morales; Femke de Vries; Michael Hultström; Anders Bergqvist; José T. Ortiz; Jan Willem Sels; Kanin Wichapong; Miklos Lipcsey; Marcel van de Poll; Anders Larsson; Tomas Luther; Chris Reutelingsperger; Pablo Garcia de Frutos; Robert Frithiof; Gerry A.F. Nicolaes

    doi:10.21203/rs.3.rs-52432/v1 Date: 2020-08-01 Source: ResearchSquare

    Background Coronavirus disease MESHD 19 ( COVID-19 MESHD) is known to present with disease severities of varying degree. In its most severe form, infection may lead to respiratory failure HP respiratory failure MESHD and multi-organ dysfunction MESHD. Here we study the levels of extracellular histone H3 (H3), neutrophil elastase (NE) and cfDNA in relation to other plasma SERO parameters, including the immune modulators GAS6 and AXL, ICU scoring systems and mortality in patients with severe COVID-19 MESHD.Methods We measured plasma SERO H3, NE, cfDNA, GAS6 and AXL concentration in plasma SERO of 83 COVID-19 MESHD-positive and 11 COVID-19 MESHD-negative patients at admission to the Intensive Care Unit (ICU) at the Uppsala University hospital, a tertiary hospital in Sweden and a total of 333 samples obtained from these patients during the ICU-stay. We determined their correlation with disease severity, organ failure MESHD, mortality and other blood SERO parameters.Results H3, NE, cfDNA, GAS6 and AXL were increased in plasma SERO of COVID-19 MESHD patients compared to controls. cfDNA and GAS6 decreased in time in in patients surviving to 30 days post ICU admission. Plasma SERO H3 was a common feature of COVID-19 MESHD patients, detected in 40% of the patients at ICU admission. Although these measures were not predictive of the final outcome of the disease, they correlated well with parameters of tissue damage (H3 and cfDNA) and neutrophil counts (NE). A subset of samples displayed H3 processing, possibly due to proteolysis.Conclusions Elevated H3 and cfDNA levels in COVID-19 MESHD patients illustrate the severity of the cellular damage observed in critically ill COVID-19 MESHD patients. The increase in NE indicates the important role of neutrophil response and the process of NETosis in the disease MESHD. GAS6 appears as part of an early activated mechanism of response in Covid-19 MESHD.

    A Comprehensive Evaluation of Early Predictors of Disease MESHD Progression in Patients with COVID-19 MESHD: A Case Control Study

    Authors: Qiang Tang; Yanwei Liu; Yingfeng Fu; Ziyang Di; Kailiang Xu; Bo Tang; Hui Wu; Maojun Di

    doi:10.21203/rs.3.rs-50527/v1 Date: 2020-07-29 Source: ResearchSquare

    Background: The 2019 coronavirus disease MESHD ( COVID-19 MESHD) has become an unprecedented public health crisis with nearly 16 million confirmed cases TRANS and 630,000 deaths worldwide. Methods: We retrospectively investigated the demographic, clinical, laboratory, radiological and treatment data of COVID-19 MESHD patients consecutively enrolled from January 18 to May 15, 2020, in Taihe and Jinzhou central hospital. Results: Of all 197 patients, the median age TRANS was 66.5 years (IQR 7-76), and 120 (60.9%) patients were males TRANS. We identified 88 (44.7%) of 197 COVID-19 MESHD patients as the disease progression (aggravation) cases. The aggravation cases tend to have more medical comorbidity: hypertension HP hypertension MESHD (34.1%), diabetes MESHD (30.7%), and presented with dyspnea MESHD dyspnea HP (34.1%), neutrophilia HP (60.2%), and lymphocytopenia MESHD (73.9%), compared with those without. And the patients with disease progression showed significantly higher level of Fibrinogen (Fbg), D-dimer, IL-6, C-reactive protein (CRP), procalcitonin (PCT), and serum SERO ferritin, and were more prone to develop organ damage in the liver, kidney, and heart (P<0.05). Multivariable regression showed that advanced age TRANS, comorbidities, lymphopenia HP lymphopenia MESHD, and elevated level of Fbg, lactate dehydrogenase (LDH), Cardiac troponin (CTnI), IL-6, serum SERO ferritin were the significant predictors of disease progression. Further, we investigated antibody SERO responses to SARS-CoV-2 and found that the levels of IgM and IgG were significantly higher in the disease progression cases compared to non-progression cases from 3 weeks after symptom onset TRANS. In addition, the disease progression group tended to peak later and has a more vigorous IgM/IgG response against SARS-CoV-2. Further, we performed Kaplan-Meier analysis and found that 61.6% of patients had not experienced ICU transfer or survival from hospital within 25 days from admission.Conclusions: Investigating the potential factors of advanced age TRANS, comorbidities and elevated level of IL-6, serum SERO ferritin and Kaplan-Meier analysis enables early identification and management of patients with poor prognosis. Detection of the dynamic antibody SERO may offer vital clinical information during the course of SARS-CoV-2 and provide prognostic value for patients infection.  

    Clinical Characteristics of COVID-19 MESHD and the Value of Mulbsta Scoring System in Prognosis Evaluation

    Authors: Chao Wang; Zhixiu Luo; Junyi Wu; Jie Zhou; Yahang Lin; Guilin Yan; Manman Yan; Xi Wang; Hanhua Yu; Xiaoyun Zeng

    doi:10.21203/rs.3.rs-35521/v1 Date: 2020-06-14 Source: ResearchSquare

    Background COVID-19 MESHD, a worldwideinfectious disease MESHD, has killed more than 420000 people, whichis extremely harmful.MethodsIn this single-center retrospective study, we included the novel coronavirus pneumonia MESHD pneumonia HP confirmed in our hospital. This study collected the basic information andclinical examination features.ResultsThe enrolled 704 patients were affirmed infected with 2019-nCoV by the test of throat swabs. There are 334 men and 369 women, and gender TRANS, age TRANS, combined with basic diseasesare distinct in diverse disease classification (p<0.05). From the symptom analysis, the proportion of fever HP fever MESHD over 38 degrees, dyspnea HP dyspnea MESHD, fatigue MESHD fatigue HP, poor appetite HP and other symptoms is diverse in different types of diseases (p<0.05). As the severity of the disease increases, the median lymphocyte count decreases, C-reactive protein increase, erythrocyte sedimentation rateincrease, albumin decrease, pleural effusion HP pleural effusion MESHD increase, D-Dimer and NT-proBNP increase significantly (p<0.05).As the disease severity increases, the average value of MuLBSTA score obviously ascend (p<0.05), MuLBSTA scoring system predicts novel coronavirus pneumonia MESHD pneumonia HP patients' prognosis is still insufficient, and may require additional indicators including anorexia HP anorexia MESHD, fatigue HP fatigue MESHD, C reactive protein, etc (p<0.05).ConclusionThe MuLBSTA evaluation system has certain value for the evaluation of the disease, but it needs to be improved.

    In silico multi-epitope vaccine against covid19 MESHD showing effective interaction with HLA-B*15:03

    Authors: Muniba Faiza; Tariq Abdullah; Jose Franklin Calderon-Tantalean; Manish Ravindranath Upadhyay; Abdelrahman H. Abdelmoneim; Fareeha Akram; Bhupender Singh Thakur; Ibrahim Abdulaziz; Chimaobi James Ononamadu; Dina Abdelazim Ghoraba; Saba Munawar; MD Fakhrul Islam Faruque; Collins Kigen; Abhishek Sharma; Ashwani Kumar; Aqsa Khalid; Ali Gharip; Ankit Gupta; Manne Manikumar; Uma Chaudhary

    doi:10.1101/2020.06.10.143545 Date: 2020-06-14 Source: bioRxiv

    The recent outbreak of severe acute respiratory syndrome MESHD (SARS) coronavirus (CoV)-2 (SARS-CoV-2) causing coronavirus disease MESHD ( covid19 MESHD) has posed a great threat to human health. Previous outbreaks of SARS-CoV MESHD and Middle East respiratory Syndrome CoV MESHD (MERS-CoV) from the same CoV family had posed similar threat to human health and economic growth. To date, not even a single drug specific to any of these CoVs has been developed nor any anti-viral vaccine is available for the treatment of diseases MESHD caused by CoVs. Subunits present in spike glycoproteins of SARS-CoV MESHD and SARS-CoV-2 are involved in binding to human ACE2 Receptor which is the primary method of viral invasion. As it has been observed in the previous studies that there are very minor differences in the spike glycoproteins of SARS-CoV MESHD and SARS-CoV-2. SARS-CoV-2 has an additional furin cleavage site that makes it different from SARS-CoV MESHD (Walls et al., 2020). In this study, we have analyzed spike glycoproteins of SARS-CoV-2 and SARS-CoV MESHD phylogenetically and subjected them to selection pressure analysis. Selection pressure analysis has revealed some important sites in SARS-CoV-2 and SARS-CoV spike glycoproteins MESHD that might be involved in their pathogenicity. Further, we have developed a potential multi-epitope vaccine candidate against SARS-CoV-2 by analyzing its interactions with HLA-B*15:03 subtype. This vaccine consists of multiple T-helper (TH) cells, B-cells, and Cytotoxic T-cells (CTL) epitopes joined by linkers and an adjuvant to increase its immunogenicity. Conservation of selected epitopes in SARS, MERS, and human hosts, suggests that the designed vaccine could provide cross-protection. The vaccine is designed in silico by following a reverse vaccinology method acknowledging its antigenicity, immunogenicity, toxicity MESHD, and allergenicity. The vaccine candidate that we have designed as a result of this work shows promising result indicating its potential capability of simulating an immune response.

    Global research trend in the treatment of the new Coronavirus diseases ( COVID-19 MESHD) : bibliometric analysis.

    Authors: Maxime Descartes Mbogning Fonkou; Abdourahamane YACOUBA

    doi:10.1101/2020.06.13.20122762 Date: 2020-06-14 Source: medRxiv

    The Coronavirus 2019 ( COVID-19 MESHD) pandemic has caused worldwide concern and has become a major medical problem. Vaccines and therapeutics are important interventions for the management of this outbreak. This study aims to used bibliometric methods to identify research trends in the domain of therapeutics and vaccines to cure patients with COVID-19 MESHD since the beginning of the pandemic. The Web of Science Core Collection database was retrieved for articles on therapeutic approaches to coronavirus disease MESHD management published between January 1, 2020 and May 20, 2020. Identified and analyzed the data included title, corresponding author, language, publication time, publication type, research focus. A total of 1569 articles on coronavirus therapeutic means from 84 countries were published in 620 journals. We note the remarkable progressive increase in the number of publications related to research on therapies and vaccines for COVID-19 MESHD. The United States provided the largest number of articles (405), followed by China (364). Journal of Medical Virology published most of them (n=40). 1005 (64.05%) were articles, 286 (18.23%) were letters, 230 (14.66%) were reviews. The terms "COVID- 19" or " SARS-CoV-2" MESHD or "Coronavirus" or "hydroxychloroquine" or "chloroquine" or "2019-nCOV" or "ACE2" or "treatment" or "remdesivir" or " pneumonia HP pneumonia MESHD" were most frequently used, as shown in the density visualization map. A network analysis based on keyword co-occurrence revealed five distinct types of studies: clinical, biological, epidemiological, pandemic management, and therapeutics (vaccines and treatments). COVID-19 MESHD is a major disease that has had an impact on international public health at the global level. Several avenues for treatment and vaccines have been explored. Most of them focus on older drugs used to treat other diseases MESHD that have been effective for other types of coronaviruses. There is a discrepancy in the results obtained from the studies of the drugs included in this study. Randomized clinical trials are needed to evaluate older drugs and develop new treatment options.

    Clinical Characteristics of 538 Novel Coronavirus Disease MESHD Patients with Chronic Underlying Diseases MESHD in Wuhan, China: A retrospective Study

    Authors: Wanwan Yi; Xiaqing Yu; Hengwei Fan; Hengmei Zhu; Zhongwei Lv; Xiaohui Fu; Qian Zhang

    doi:10.21203/rs.3.rs-30703/v1 Date: 2020-05-21 Source: ResearchSquare

    Background Novel severe acute respiratory syndrome MESHD coronavirus 2 causes the novel coronavirus disease MESHD ( COVID-19 MESHD) in humans, which has spread rapidly worldwide. Most critical cases of COVID-19 MESHD are accompanied by complicated chronic underlying diseases. This retrospective study aims to analyze the clinical characteristics of COVID-19 MESHD patients with chronic underlying diseases.Methods A total of 1,183 COVID-19 MESHD patients were divided into the chronic underlying disease ( CUD MESHD, n = 538) group and the non-underlying disease (non-CUD, n = 645) group. The clinical characteristics and outcomes were collected and compared between the two groups.Results There were significant differences in age TRANS, weight, and SPO2 on admission between the CUD and non-CUP groups. The ratio of severe cases in the CUD group was higher than that in the non-CUD group (χ2 = 35.58, p-value < 0.001). The white blood SERO cell count, neutrophil count, C-reactive protein, urea nitrogen, creatinine, myoglobin, and cardiac troponin in the CUD group were significantly higher than those in the non-CUD group, while the lymphocyte count and albumin in the underlying disease group were significantly lower than those in the non-underlying disease group. No significant difference was found in the total number of tests, the number of positive or negative results in nucleic acid tests between the two groups. The negative rate for both IgG- and IgM-antibody tests SERO in the CUD group was higher than that in the non-CUD group (χ2 = 5.57, p-value = 0.018). No statistical difference in mortality between the CUD (n = 18) and non-CUD groups (n = 13). All surviving patients were cured and discharged. A total of 33 patients had a positive re-examination result for nucleic acid test one week after discharge, including 14 patients with underlying diseases and 19 patients without underlying diseases. Conclusion: COVID-19 MESHD patients with underlying diseases had poorer clinical conditions and had a longer hospital stay, but after active treatment, the mortality had not increased significantly.

    Structure-Based Screening of Novel Lichen Compounds for SARS Coronavirus MESHD Main protease (Mpro) and Angiotensin-Converting Enzyme 2 (ACE2) inhibitory potentials as multi-target inhibitors of COVID-19 MESHD

    Authors: Tanuja Joshi; Priyanka Sharma; Tushar Joshi; Hemlata Pundir; Shalini Mathpal; Subhash Chandra

    doi:10.21203/rs.3.rs-26207/v1 Date: 2020-04-29 Source: ResearchSquare

    Outbreak of SARS-CoV-2 and massing death caused by it all over world has imposed great concern on scientific community to develop potential drugs to combat with Coronaviruas disease MESHD 19 ( COVID-19 MESHD ). In this regard, lichen metabolites may offer a vast reservoir for discovery of anti-viral drug candidates. Therefore to find novel compounds against COVID-19 MESHD, we created a library of 412 lichen compounds and subjected to virtual screening against two molecular targets; SARS-CoV-2  target- Main protease (Mpro) and host cell target- Angiotensin-converting enzyme 2 (ACE2). All the ligands were virtually screened, and 80 compounds were found to have better docking score with both the targets. These compounds were assessed for druglikeness analysis where 27 compounds were found to fit well for redocking studies. The results of redocking by X-Score showed that 7 out of 27 compounds were found to have high affinities with Mpro as well ACE2 which reflect that these compounds can function as dual inhibitors.  Molecular docking, druglikeness, X-Score and toxicity MESHD analysis resulting seven novel lichen compounds (Orcinyllecanorate, Siphulin, Fremontol, Gyrophoric acid, Rhizocarpic acid, Ovoic acid, and Umbilicaric acid) with Mpro and ACE2 multi-target activities and they can be used as hit compounds to develop potential antiviral agents against SARS-CoV-2. These lichen compounds may be a suitable candidate for further experimental analysis.

    Clinical Characteristics of 208 Patients with COVID-19 MESHD in a Surrounding City of Wuhan, China

    Authors: Xin Chen; Peng Chen; Dodji Kossi Djakpo; Yan Lin; Rong Zhang; Zhiquan Wang

    doi:10.21203/rs.3.rs-23842/v1 Date: 2020-04-19 Source: ResearchSquare

    Background: Since December 2019, a severe novel coronavirus ( SARS-CoV-2) infection (Coronavirus Disease MESHD Coronavirus Disease 2019 MESHD, COVID-19 MESHD) has occurred in Wuhan, China, and has rapidly spread to the country and around the world. This study intends to investigate the epidemiological and clinical characteristics of patients with COVID-19 MESHD in a surrounding city of Wuhan.Methods: A retrospective study was conducted on 208 cases of COVID -19 patients from February 11, 2020 to February 29, 2020 in Xiaogan dongnan Hospital, collected basic information, history of exposure, medical history, clinical symptoms, laboratory indicators and pulmonary imaging Data, and analyzed the epidemiological and clinical characteristics of all patients. According to the clinical classification criteria, 208 patients were divided into light group and ordinary group, and the epidemiological and clinical characteristics of the two groups were compared.Results: Among 208 patients in this study, with a median age TRANS of 50.5 years (IQR,36-64.7,range,10-91 years), among which 107 (51.4%) were males TRANS and 101 (48.6%) were females TRANS. 51 (24.5%) had a clear exposure to COVID-19 MESHD infection within 2 weeks before admission, and 40 (19.2%) had a history of residence or exposure in Wuhan within 2 weeks before admission. Among all the patients, there were 16 (7.7%) with pulmonary diseases MESHD, 41 (19.7%) with hypertension HP hypertension MESHD, 11 (5.3%) with coronary heart disease MESHD, 13 (6.3%) with diabetes MESHD, 12(5.8%) with a history of alcohol consumption, and 12(5.8%) with a history of smoking. Among all clinical symptoms, 146 cases (70.2%) of fever HP fever MESHD, the highest temperature range was 37.3℃-41℃ before admission, 115 (55.3%) cases of cough HP, and 57 (27.4%) cases of chest tightness HP chest tightness MESHD, 47 (22.6%) cases of fatigue HP fatigue MESHD, 28 (13.5%) cases of inappetence, 9 (4.3%) cases of diarrhea HP diarrhea MESHD, 7 (3.4%) cases of nasal congestion or runny nose , and 5 ( 2.4%) cases of pharyngalgia. Analysis of the laboratory results of 208 patients showed that 42 (20.2%) cases had decreased white blood SERO cell count, and 61 (29.3%) cases had decreased lymphocyte count. There were 154 (74%) cases with elevated CRP, 50 (24%) cases with elevated fasting blood SERO glucose, and 23 (11.1%) cases with elevated LDH (>245U/L). The comparison of clinical characteristics between the light group and the common group showed that the median age TRANS of the light group was 44.8 years (IQR 30-58), the median age TRANS of the common group was 53.1 years (IQR 38.8-67) (P<0.01). The symptoms of fever MESHD fever HP [53(80.3%) vs 93(65.5%),P<0.05], fatigue HP fatigue MESHD [53(80.3%) vs 93(65.5%),P<0.05] and inappetence [4(6.1%) vs 24(16.9%),P<0.05] in the light group were less than those in the common group. The white blood SERO cell count (5.48 vs 6.37, P<0.05), lymphocyte count (1.40 vs 1.61, P<0.05) and HDL-C (1.5 vs 1.3, P<0.05) of the common group were lower than that of the light group, while CRP (26.5 vs 22.1, P<0.01), AST (22.9 vs 18.5, P<0.05), fasting blood SERO glucose (5.8 vs 5.6, P<0.05), LDH (196.8 vs 157.9, P<0.001) of the common group were higher than that of the light group.Conclusion: COVID-19 MESHD infection is mainly in middle- aged TRANS and elderly TRANS patients, patients with other diseases MESHD are more susceptible to infection. The main symptoms of COVID-19 MESHD infection were fever HP fever MESHD, cough MESHD cough HP, chest tightness MESHD chest tightness HP, fatigue HP fatigue MESHD, and inappetence. Decreased lymphocyte count, increased CRP concentration, increased LDH concentration and decreased HDL-C concentration were the laboratory features of COVID-19 MESHD infection, and were important indicators to assess the severity of COVID-19 MESHD disease.

    Feasibility of Known RNA Polymerase Inhibitors as Anti-SARS-CoV-2 Drugs

    Authors: Ujjwal Neogi; Kyle J. Hill; Anoop T. Ambikan; Xiao Heng; Thomas P. Quinn; Siddappa N. Byrareddy; Anders Sönnerborg; Stefan G. Sarafianos; Kamal Singh

    id:10.20944/preprints202004.0184.v1 Date: 2020-04-12 Source: Preprints.org

    Coronaviruses (CoVs) are positive-stranded RNA viruses that infect MESHD humans and animals. Infection by CoVs such as HCoV-229E, -NL63, -OC43 and -HKUI1 leads to the common cold, short lasting rhinitis MESHD rhinitis HP, cough HP, sore throat and fever MESHD fever HP. However, CoVs such as Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV), Middle East Respiratory Syndrome Coronavirus (MERS-CoV) MESHD, and the newest SARS-CoV-2 (the causative agent of COVID-19 MESHD) lead to severe and deadly diseases MESHD with mortality rates ranging between ~1 to 35% depending on factors such as age TRANS and pre-existing conditions. Despite continuous global health threats to human, there are no approved vaccines or drugs targeting human CoVs, and the recent outbreak of COVID-19 MESHD emphasizes an urgent need for therapeutic interventions. Using computational and bioinformatics tools, here we present the feasibility of reported broad-spectrum RNA polymerase inhibitors as anti- SARS-CoV-2 drugs targeting its main RNA polymerase, suggesting that investigational and approved nucleoside RNA polymerase inhibitors have potential as anti-SARS-CoV-2 drugs. However, we note that it is also possible for SARS-CoV-2 to evolve and acquire drug resistance mutations against these nucleoside inhibitors.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.